Canadian Court Upholds Lipitor In Crystal Form

Law360, New York (September 13, 2007, 12:00 AM EDT) -- A federal court in Canada has ruled that Pfizer Inc.’s patent covering the key ingredient in Lipitor would be infringed by Ranbaxy Laboratories Ltd.’s method for developing a generic copy of the cholesterol-lowering drug.

Pfizer, the world’s biggest pharmaceutical company, said Wednesday that the Canadian Federal Court in Toronto barred the Indian generics maker from marketing and selling its generic version of a crystalline form of atorvastatin, the active component in Lipitor, until the Canadian patent expires in July 2016.

However, the court found that Ranbaxy’s...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.